Financial Advocates Investment Management Acquires 11,000 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Financial Advocates Investment Management raised its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 28.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,000 shares of the company’s stock after purchasing an additional 11,000 shares during the period. Financial Advocates Investment Management’s holdings in Aquestive Therapeutics were worth $178,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of AQST. nVerses Capital LLC bought a new stake in Aquestive Therapeutics during the 3rd quarter valued at $28,000. China Universal Asset Management Co. Ltd. bought a new stake in Aquestive Therapeutics during the 4th quarter valued at $69,000. The Manufacturers Life Insurance Company bought a new stake in Aquestive Therapeutics during the 2nd quarter valued at $76,000. Harvey Capital Management Inc. bought a new stake in Aquestive Therapeutics during the 3rd quarter valued at $88,000. Finally, Intech Investment Management LLC bought a new stake in Aquestive Therapeutics during the 3rd quarter valued at $90,000. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Trading Up 1.0 %

Shares of NASDAQ:AQST opened at $2.99 on Tuesday. Aquestive Therapeutics, Inc. has a 12-month low of $2.24 and a 12-month high of $6.23. The business’s fifty day simple moving average is $3.44 and its 200-day simple moving average is $4.21. The company has a market capitalization of $272.62 million, a PE ratio of -6.64 and a beta of 2.67.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on AQST shares. Leerink Partners lifted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday, December 20th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $11.00.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.